Trial Profile

A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jan 2022 Results assessing the antiviral effect, safety, tolerability, and PK of once-daily GSK3640254 monotherapy administered with food (moderate-fat meal) in HIV-1 positive, treatment-naive adults, published in the Clinical Infectious Diseases.
10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections
09 Mar 2021 According to a ViiV Healthcare Media Release, a planned interim analysis showed treatment emergent resistance associated mutations in the 200 mg arm after dosing was complete.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com